In brief
L'Oreal notes that GLP‑1 weight‑loss medications are changing consumer behavior in the beauty sector, driving the launch of new skin‑care lines that address loose skin from rapid weight loss. The company’s sales rose 7.7 percent in the latest quarter, showing resilience amid global economic challenges. To support these trends, L'Oreal has expanded its partnership with dermatology firm Galderma, offering products that stimulate collagen and fill volume. Clinical trials are underway to evaluate these solutions in people who have used GLP‑1 drugs. The convergence of medical innovation and cosmetic branding highlights the evolving demands faced by brands worldwide.
L'Oreal has reported that a surge in prescribing GLP‑1 weight‑loss medications is reshaping beauty and skin‑care demand, prompting the company to tailor new product lines to the side effects of rapid weight loss.
The executive chair said the firm’s quarterly sales grew 7.7 percent, surpassing expectations, yet the uptick also signals a broader shift that the beauty market must address in the coming years.
To meet changing consumer needs, L'Oreal’s SkinCeuticals and Kiehl's divisions have introduced formulations that support skin firmness and collagen production, targeting the loose skin that some users experience after losing weight quickly.
In parallel, the company has increased its stake in dermatology specialist Galderma, where injectables that stimulate collagen and fill volume are on the shelf, a partnership that underscores the blend of medical and cosmetic innovation.
Surveys carried out by the aesthetic firm reveal that most people using GLP‑1 drugs notice changes to their facial shape, an observation that has led both brands and research groups to run clinical trials on these consumers.
This trend illustrates how advances in medical science are outpacing traditional beauty expectations, creating an environment in which brands must adapt while consumers seek products that align with new bodily realities.
